ArticleCureus2025
Bladder Metastasis From Lung Adenocarcinoma: A Rare Case.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnostic challenges in a rare case of bladder metastasis from lung hepatoid adenocarcinoma: The first reported case.Urology case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder metastasis from primary lung adenocarcinoma is an infrequent clinical entity. Due to its rarity and nonspecific presentation, it is often misdiagnosed as primary urothelial carcinoma. We report the case of a 65-year-old male with a history of metastatic lung adenocarcinoma presenting to the emergency room with sudden gross hematuria. Imaging revealed a new bladder lesion. Following transurethral resection, histopathological and immunohistochemical analysis confirmed metastatic lung adenocarcinoma (thyroid transcription factor-1-positive/cytokeratin 7-positive/cytokeratin 20 negative/GATA binding protein 3-negative or TTF-1+/CK7+/CK20-/GATA3-). The case was discussed at the Genitourinary Oncology Tumor Board, and given the prognosis of metastatic lung adenocarcinoma, the patient opted for palliative care. This case highlights the importance of considering metastatic spread to the urinary bladder in patients with advanced malignancy who develop new urinary symptoms. Accurate diagnosis through histopathology and immunohistochemistry is essential for guiding appropriate management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.